PGF

Summary

PGF (placental growth factor, HGNC:8893) is a protein-coding gene on chromosome 14q24.3, encoding Placenta growth factor (P49763). Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration.

Enables growth factor activity. Involved in positive regulation of cell population proliferation. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Implicated in several diseases, including brain ischemia; diabetic neuropathy; glioblastoma; myocardial infarction; and pancreatic endocrine carcinoma. Biomarker of several diseases, including artery disease (multiple); autoimmune disease of musculoskeletal system (multiple); epilepsy (multiple); limited scleroderma; and pancreatic endocrine carcinoma.

Source: NCBI Gene 5228 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 38 total
• Druggable target: yes
• MANE Select transcript: NM_002632

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8893
Approved symbol	PGF
Name	placental growth factor
Location	14q24.3
Locus type	gene with protein product
Status	Approved
Aliases	PlGF-2, SHGC-10760, D12S1900, PIGF, PLGF, PlGF
Ensembl gene	ENSG00000119630
Ensembl biotype	protein_coding
OMIM	601121
Entrez	5228

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 4 retained_intron

ENST00000238607, ENST00000405431, ENST00000553716, ENST00000555234, ENST00000555253, ENST00000555567, ENST00000556939, ENST00000557748, ENST00000863243, ENST00000863244, ENST00000965660

RefSeq mRNA: 3 — MANE Select: NM_002632 NM_001207012, NM_001293643, NM_002632

CCDS: CCDS55932, CCDS73664, CCDS9835

Canonical transcript exons

ENST00000555567 — 7 exons

Exon	Start	End
ENSE00001195853	74946213	74946275
ENSE00002468846	74955168	74955597
ENSE00002473068	74941834	74942733
ENSE00003482136	74949357	74949553
ENSE00003526402	74946379	74946408
ENSE00003607518	74953904	74953946
ENSE00003664306	74948507	74948583

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 99.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.3667 / max 403.8345, expressed in 985 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
144092	8.3667	985

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
renal medulla	UBERON:0000362	99.60	gold quality
cardia of stomach	UBERON:0001162	99.49	gold quality
pylorus	UBERON:0001166	99.41	gold quality
nipple	UBERON:0002030	99.38	gold quality
ventral tegmental area	UBERON:0002691	99.35	gold quality
trigeminal ganglion	UBERON:0001675	99.27	gold quality
inferior vagus X ganglion	UBERON:0005363	99.26	gold quality
lateral globus pallidus	UBERON:0002476	99.25	gold quality
superior surface of tongue	UBERON:0007371	99.25	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.24	gold quality
subthalamic nucleus	UBERON:0001906	99.22	gold quality
superior vestibular nucleus	UBERON:0007227	99.20	gold quality
superficial temporal artery	UBERON:0001614	99.19	gold quality
medulla oblongata	UBERON:0001896	99.19	gold quality
substantia nigra pars compacta	UBERON:0001965	99.13	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.09	gold quality
endothelial cell	CL:0000115	99.00	gold quality
mucosa of paranasal sinus	UBERON:0005030	98.99	gold quality
pericardium	UBERON:0002407	98.98	gold quality
synovial joint	UBERON:0002217	98.94	gold quality
buccal mucosa cell	CL:0002336	98.91	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	98.90	gold quality
penis	UBERON:0000989	98.87	gold quality
sperm	CL:0000019	98.85	gold quality
urethra	UBERON:0000057	98.82	gold quality
male germ cell	CL:0000015	98.79	gold quality
saphenous vein	UBERON:0007318	98.76	gold quality
inferior olivary complex	UBERON:0002127	98.75	gold quality
pharyngeal mucosa	UBERON:0000355	98.73	gold quality
epithelium of nasopharynx	UBERON:0001951	98.68	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-10018	yes	5469.95
E-MTAB-10662	yes	2802.17
E-MTAB-6701	yes	1193.67
E-HCAD-5	yes	325.75
E-MTAB-6678	yes	16.64
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): DLX3, EGR1, FOXD1, FOXG1, GCM1, HIF1A, MTF1, NR3C2, RELA, STAT3

miRNA regulators (miRDB)

52 targeting PGF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-6126	99.62	68.09	996
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-4291	99.20	68.88	2969

Literature-anchored findings (GeneRIF, showing 40)

• Maternal serum placenta growth factor concentration was elevated in Down syndrome pregnancies (PMID:11810642)
• Effect of placenta growth factor-1 on proliferation and release of nitric oxide, cyclic AMP and cyclic GMP in human epithelial cells expressing the FLT-1 receptor (PMID:11811792)
• Placental growth factor promotes recruitment of VEGFR1(+) hematopoietic stem cells from a quiescent to a proliferative bone marrow microenvironment, favoring differentiation, mobilization and reconstitution of hematopoiesis. (PMID:12091880)
• increased inflammatory response, associated with more pronounced vascular enlargement, edema, and inflammatory cell infiltration in transgenic mice (PMID:12393422)
• Vitreous levels are altered in patients with proliferative diabetic retinopathy (PMID:12453985)
• This protein and its receptor VEGR-1 are novel therapeutic targets for angiogenic disorders (REVIEW) (PMID:12543719)
• placenta growth factor-to-human chorionic gonadotropin ratios were increased significantly in patients with persistent gestational trophoblastic disease (PMID:12548207)
• postulate that decreased placental growth factor production results in abnormalities of placental angiogenesis through direct and indirect effects on other vasculotropic growth factors (PMID:12548214)
• findings point to a role for PlGF in rapid restoration of tumor blood supply after treatment and thus, to enhanced likelihood of tumor regrowth (PMID:12673673)
• Placenta growth factor contributes to the inflammation observed in sickle cell disease and increases the incidence of vaso-occlusive events. (PMID:12714517)
• alteration of PlGF-2 and PlGFR-1 mRNA expressions in the placenta are related to the pathogenesis of pregnancy induced hypertension (PMID:12808329)
• paracrine role for mesenchynmal stem cell-derived PlGF in the angiogenesis and hematopoiesis that accompany BMP-2-induced bone formation. (PMID:13678785)
• Ang2, PIGF and VEGF-C play a role in promote endothelial survival and vascular remodeling by human cytotrophoblast. (PMID:14568550)
• findings suggest that production of placental growth factor is sensitive to the cyclic changes in ovarian steroids and may contribute to the pathogenesis of endometriosis (PMID:14645176)
• crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1 (PMID:14684734)
• VEGF and PlGF induced expression of both full-length FosB mRNA and an alternatively spliced variant. (PMID:14741347)
• vascular endothelial growth factor and placental growth factor-2 effects in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production (PMID:15126502)
• a basis for understanding molecular recognition between PlGF-1 and VEGFR1 (PMID:15272021)
• effect of VEGFA and PLGF on gene expression profiles obtained for HUVEC, dose effect, and variability between cells obtained from different individuals (PMID:15516835)
• vascular endothelial growth factor induced the production of PlGF protein (PMID:15710418)
• In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in small for gestational age pregnancies in the absence of a maternal syndrome (PMID:15886253)
• Altered expression of Fas, FasL and PGF in trophoblasts of placenta influence the pathogenesis of pre-eclampsia. (PMID:15938782)
• These findings are consistent with the idea that the chemotactic effect of VEGF-A on mesenchymal progenitor cells (MPC) is mediated via VEGFR-1, and that VEGF-A and PlGF-1, have a functional role for recruitment of osteoprogenitor cells. (PMID:16005848)
• growth stimulation of ALL cells by PlGF was confirmed by the increase of S phase cells; the growth promoting effect of PlGF was cancelled by simultaneous addition of VEGFR1/Fc), but was not cancelled by VEGFR2/Fc (PMID:16146532)
• Correlation of placenta growth factor expression and placental perfusion suggests that placenta growth factor may contribute to assuring adequate vascular development/function of the placenta early in gestation. (PMID:16635470)
• Therapeutically administered human PIGF-1 demonstrates a desirable biological activity for promoting the growth of functionally relevant vasculature in mice. (PMID:16702473)
• Overexpression of VEGF but not PIGF exacerbated the lipopolysaccharide-mediated toxic effects, supporting a pathophysiological role for VEGF in mediating the sepsis phenotype. (PMID:16702604)
• Neither the hyperpermeability in response to simultaneous stimulation of VEGFR-1 and VEGFR-2 nor VEGFR-1-mediated severe inflammation was associated with VEGF-E(NZ7)/PIGF-induced angiogenesis. (PMID:16794222)
• iodide at high concentration decreases the expression of the angiogenic factors VEGF-A, VEGF-B, and PG (PMID:16839256)
• The strong positivity for both PlGF and VEGF observed, implies that the t(10;14)(p13;q24) most likely involves PlGF, which may be one of the genes driving oncogenesis in these tumors. (PMID:16843105)
• The expression and localization of placenta growth factor (PlGF) within middle ear cholesteatoma were defined (PMID:16864484)
• These data suggest that mechanical stretch of bronchial airway epithelial cells induces iNOS expression and induces PIGF release in an erk1/2 activation-dependent manner. (PMID:17028267)
• placental growth factor-expression within human atherosclerotic lesions is associated with plaque inflammation and microvascular density (PMID:17157858)
• May be a potential regulation target for the control of diabetic retinal and macular oedema. (PMID:17187248)
• The plasma PIGF level in coronary artery disease group was significantly higher than that in the control group (PMID:17593833)
• PGF and VEGFR1 may have an important role in the pathogenesis of the neovascular response in cirrhosis. (PMID:17696935)
• Promoter is methylated, and methylation may be one of the mechanisms that contributes to the low PGF expression level in human lung and colorectal tumor tissues and cell lines. (PMID:17704140)
• Preeclampsia trophoblast cells produce more sEng, sFlt-1, and PlGF than normal TCs. Lowered oxygen conditions promote sEng and sFlt-1, but reduce PlGF, productions by PE TCs. (PMID:17956952)
• anlalysis of levels of circulating PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus (PMID:17964973)
• sFlt-1 and PlGF and their ratio relative to one another may play a role in the development of preeclampsia (PMID:17982238)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	pgfb	ENSDARG00000076767
danio_rerio		ENSDARG00000115359
mus_musculus	Pgf	ENSMUSG00000004791
rattus_norvegicus	Pgf	ENSRNOG00000005650

Paralogs (4): VEGFA (ENSG00000112715), VEGFC (ENSG00000150630), VEGFD (ENSG00000165197), VEGFB (ENSG00000173511)

Protein

Protein identifiers

Placenta growth factor — P49763 (reviewed: P49763)

All UniProt accessions (3): P49763, G3XA84, Q53XY6

UniProt curated annotations — full annotation on UniProt →

Function. Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.

Subunit / interactions. Antiparallel homodimer; disulfide-linked. Also found as heterodimer with VEGFA/VEGF. Isoform PlGF-3 is found both as homodimer and as monomer.

Subcellular location. Secreted.

Tissue specificity. While the three isoforms are present in most placental tissues, PlGF-2 is specific to early (8 week) placenta and only PlGF-1 is found in the colon and mammary carcinomas.

Post-translational modifications. N-glycosylated.

Domain organisation. Isoform PlGF-2 contains a basic insert which acts as a cell retention signal.

Similarity. Belongs to the PDGF/VEGF growth factor family.

Isoforms (4)

UniProt ID	Names	Canonical?
P49763-1	PlGF-3, PlGF-203	yes
P49763-2	PlGF-1, PlGF-131
P49763-3	PlGF-2, PlGF-152
P49763-4	PlGF-4, PlGF-224

RefSeq proteins (3): NP_001193941, NP_001280572, NP_002623* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000072	PDGF/VEGF_dom	Domain
IPR023581	PD_growth_factor_CS	Conserved_site
IPR029034	Cystine-knot_cytokine	Homologous_superfamily
IPR050507	PDGF/VEGF_growth_factor	Family

Pfam: PF00341

UniProt features (24 total): strand 6, disulfide bond 5, splice variant 2, helix 2, region of interest 2, compositionally biased region 2, glycosylation site 2, signal peptide 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
1FZV	X-RAY DIFFRACTION	2
1RV6	X-RAY DIFFRACTION	2.45

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49763-F1	71.00	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 83–128, 86, 87–130, 52–94, 77

Glycosylation sites (2): 33, 101

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-194313	VEGF ligand-receptor interactions
R-HSA-195399	VEGF binds to VEGFR leading to receptor dimerization

MSigDB gene sets: 534 (showing top): RNGTGGGC_UNKNOWN, HORIUCHI_WTAP_TARGETS_DN, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, GOBP_VASCULAR_ENDOTHELIAL_GROWTH_FACTOR_SIGNALING_PATHWAY, PAX4_01, GOBP_MYELOID_LEUKOCYTE_MIGRATION, HARRIS_HYPOXIA, MORF_MSH3, GOBP_CELL_CHEMOTAXIS, GOBP_GLYCOLIPID_BIOSYNTHETIC_PROCESS, PEREZ_TP63_TARGETS, REACTOME_SYNTHESIS_OF_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI, MORF_BRCA1

GO Biological Process (13): response to hypoxia (GO:0001666), sprouting angiogenesis (GO:0002040), signal transduction (GO:0007165), cell-cell signaling (GO:0007267), positive regulation of cell population proliferation (GO:0008284), cell differentiation (GO:0030154), vascular endothelial growth factor signaling pathway (GO:0038084), vascular endothelial growth factor receptor signaling pathway (GO:0048010), induction of positive chemotaxis (GO:0050930), positive regulation of cell division (GO:0051781), positive regulation of mast cell chemotaxis (GO:0060754), angiogenesis (GO:0001525), positive chemotaxis (GO:0050918)

GO Molecular Function (6): vascular endothelial growth factor receptor binding (GO:0005172), growth factor activity (GO:0008083), heparin binding (GO:0008201), chemoattractant activity (GO:0042056), protein binding (GO:0005515), receptor ligand activity (GO:0048018)

GO Cellular Component (3): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by VEGF	1
VEGF ligand-receptor interactions	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	2
signaling	2
positive regulation of cellular process	2
cell surface receptor protein tyrosine kinase signaling pathway	2
receptor ligand activity	2
cellular anatomical structure	2
response to stress	1
response to decreased oxygen levels	1
angiogenesis	1
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
cellular developmental process	1
cellular response to vascular endothelial growth factor stimulus	1
positive regulation of positive chemotaxis	1
cell division	1
regulation of cell division	1
mast cell chemotaxis	1
positive regulation of leukocyte chemotaxis	1
regulation of mast cell chemotaxis	1
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
chemotaxis	1
cytokine receptor binding	1
growth factor receptor binding	1
glycosaminoglycan binding	1
sulfur compound binding	1
positive chemotaxis	1
binding	1
signaling receptor binding	1
signal transduction	1
signaling receptor activator activity	1

Protein interactions and networks

STRING

1372 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PGF	FLT1	P16057	999
PGF	KDR	P35968	998
PGF	FLT4	P35916	997
PGF	NRP1	O14786	997
PGF	NRP2	O60462	968
PGF	FN1	P02751	942
PGF	VEGFB	P49765	888
PGF	ENG	P17813	884
PGF	VTN	P01141	880
PGF	PDGFC	Q9NRA1	876
PGF	SPP1	P10451	850
PGF	ANGPT2	O15123	822
PGF	HGF	P14210	800
PGF	PAPPA	Q13219	798
PGF	TEK	Q02763	764

IntAct

4 interactions, top by confidence:

A	B	Type	Score
FLT1	VEGFA	psi-mi:“MI:0915”(physical association)	0.820
FLT1	PGF	psi-mi:“MI:0407”(direct interaction)	0.610
VEGFA	PGF	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (9): VEGFA (Co-localization), PGF (Affinity Capture-MS), VEGFA (Co-purification), PGF (Co-purification), PGF (Reconstituted Complex), PGF (Affinity Capture-Western), PGF (Reconstituted Complex), PGF (Affinity Capture-RNA), PGF (Affinity Capture-RNA)

ESM2 similar proteins: A2APT9, A6NKQ9, A6QNY1, B0BN44, B6VH76, B6VH77, B6VH79, F8WCM5, O00220, O75298, P0C2N6, P0CG36, P0CG37, P22618, P48778, P49763, P97766, Q1L6U9, Q29100, Q3U4N7, Q4R6Y5, Q4TUC0, Q5DRQ5, Q5F267, Q5HZW5, Q5RA67, Q63572, Q7TQH7, Q7Z3H0, Q80W87, Q866Y3, Q86VZ4, Q8BLH5, Q8C310, Q8CB67, Q8IXA5, Q8K1T6, Q8QZY4, Q8R2S1, Q8TDX9

Diamond homologs: B0VXV3, B0VXV4, C0HM96, C0K3N1, C0K3N2, C0K3N3, C0K3N4, C0K3N5, O35251, O35485, O35757, O43915, O73682, P0DL42, P0DW97, P0DW98, P15691, P15692, P16612, P26617, P49151, P49763, P49764, P49765, P49766, P49767, P50412, P52584, P52585, P67860, P67861, P67862, P67863, P67964, P67965, P82475, P83906, P83942, P97946, P97953

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Aflibercept	“down-regulates activity”	PGF	“chemical inhibition”

Disease & clinical

Clinical variants and AI predictions

ClinVar

38 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2233 predictions. Top by Δscore:

Variant	Effect	Δscore
14:74946374:CTTA:C	donor_loss	1.0000
14:74946375:TTAC:T	donor_loss	1.0000
14:74946376:TACC:T	donor_loss	1.0000
14:74946377:A:AC	donor_gain	1.0000
14:74946377:ACCTT:A	donor_loss	1.0000
14:74946378:C:CC	donor_gain	1.0000
14:74946378:CCTTT:C	donor_gain	1.0000
14:74946404:GAGGC:G	acceptor_gain	1.0000
14:74946405:AGGC:A	acceptor_gain	1.0000
14:74946406:GGC:G	acceptor_gain	1.0000
14:74946407:GC:G	acceptor_gain	1.0000
14:74946408:CC:C	acceptor_gain	1.0000
14:74946409:C:CC	acceptor_gain	1.0000
14:74946418:C:CT	acceptor_gain	1.0000
14:74946419:A:T	acceptor_gain	1.0000
14:74946422:C:CT	acceptor_gain	1.0000
14:74948502:CCTA:C	donor_loss	1.0000
14:74948503:CTA:C	donor_loss	1.0000
14:74948505:A:AC	donor_gain	1.0000
14:74948505:ACC:A	donor_loss	1.0000
14:74948506:C:CA	donor_loss	1.0000
14:74948506:C:CC	donor_gain	1.0000
14:74948506:CCGG:C	donor_gain	1.0000
14:74948584:C:CC	acceptor_gain	1.0000
14:74949355:A:AC	donor_gain	1.0000
14:74949356:C:CA	donor_loss	1.0000
14:74949356:C:CC	donor_gain	1.0000
14:74949356:CCTG:C	donor_gain	1.0000
14:74949549:TACCA:T	acceptor_gain	1.0000
14:74949550:ACCA:A	acceptor_gain	1.0000

AlphaMissense

1093 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:74949454:A:C	F73C	0.996
14:74949544:A:C	F43C	0.996
14:74948533:G:C	F122L	0.994
14:74948533:G:T	F122L	0.994
14:74948534:A:C	F122C	0.994
14:74948535:A:G	F122L	0.994
14:74949448:G:T	P75Q	0.994
14:74949419:C:A	G85C	0.993
14:74949531:C:A	W47C	0.993
14:74949531:C:G	W47C	0.993
14:74948534:A:G	F122S	0.992
14:74949522:G:C	S50R	0.992
14:74949522:G:T	S50R	0.992
14:74949524:T:G	S50R	0.992
14:74949439:A:T	V78D	0.991
14:74949449:G:A	P75S	0.991
14:74949517:C:G	C52S	0.991
14:74949518:A:T	C52S	0.991
14:74949391:C:G	C94S	0.990
14:74949392:A:T	C94S	0.990
14:74949424:C:G	C83S	0.990
14:74949425:A:G	C83R	0.990
14:74949425:A:T	C83S	0.990
14:74949517:C:T	C52Y	0.990
14:74949391:C:T	C94Y	0.989
14:74949453:G:C	F73L	0.989
14:74949453:G:T	F73L	0.989
14:74949454:A:G	F73S	0.989
14:74949455:A:G	F73L	0.989
14:74949516:G:C	C52W	0.988

dbSNP variants (sampled 300 via entrez): RS1000086247 (14:74943547 T>C), RS1000195446 (14:74950851 T>TG), RS1000200855 (14:74950606 A>G), RS1000209830 (14:74951336 G>T), RS1000255903 (14:74948083 C>G,T), RS1000346229 (14:74953222 T>C), RS1000347195 (14:74945519 G>A,T), RS1000459970 (14:74942489 T>G), RS1000517901 (14:74946103 A>G), RS1000688734 (14:74944394 G>A), RS1000801233 (14:74952038 G>A), RS1000883765 (14:74953413 G>C), RS1001256920 (14:74949033 T>C), RS1001486788 (14:74954975 C>A), RS1001548108 (14:74955654 G>A)

Disease associations

OMIM: gene MIM:601121 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST005237_3	Mood instability	1.000000e-06
GCST005238_3	Mood instability	3.000000e-09
GCST006585_2645	Blood protein levels	4.000000e-07
GCST009731_77	Blood protein levels in cardiovascular risk	3.000000e-09
GCST010002_156	Refractive error	7.000000e-25
GCST90011900_113	Serum alkaline phosphatase levels	4.000000e-15

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0008475	mood instability measurement
EFO:0010626	placenta growth factor measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1697671 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

36 potent at pChembl≥5 of 40 total, top 36 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.00	Kd	0.1	nM	CHEMBL1689483
9.52	Kd	0.3	nM	CHEMBL1689479
9.52	Kd	0.3	nM	CHEMBL1689481
9.40	IC50	0.4	nM	CHEMBL1689483
9.00	IC50	1	nM	CHEMBL1689481
8.70	IC50	2	nM	CHEMBL1689460
8.52	IC50	3	nM	CHEMBL1689482
8.40	IC50	4	nM	CHEMBL1689463
8.40	Kd	4	nM	CHEMBL1689460
8.40	Kd	4	nM	CHEMBL1689466
8.30	Kd	5	nM	CHEMBL1689463
8.30	Kd	5	nM	CHEMBL1689465
8.22	Kd	6	nM	CHEMBL1689473
8.10	Kd	8	nM	CHEMBL1689464
8.10	Kd	8	nM	CHEMBL1689482
8.09	Kd	8.2	nM	AMENTOFLAVONE
8.05	Kd	9	nM	CHEMBL1689470
8.05	Kd	9	nM	CHEMBL1689483
7.96	Kd	11	nM	CHEMBL2335722
7.64	Kd	23	nM	GERANIN B
7.00	Kd	100	nM	CHEMBL1689460
6.82	IC50	150	nM	CHEMBL1689460
6.70	Kd	200	nM	CHEMBL1689461
6.41	Kd	394	nM	PROANTHOCYANIDIN A1
6.00	IC50	1000	nM	CHEMBL1689461
6.00	Kd	1000	nM	CHEMBL1689456
6.00	IC50	1000	nM	CHEMBL1689456
6.00	IC50	1000	nM	CHEMBL1689457
6.00	IC50	1000	nM	CHEMBL1689458
6.00	IC50	1000	nM	CHEMBL1689459
5.30	IC50	5000	nM	CHEMBL1689452
5.30	IC50	5000	nM	CHEMBL1689455
5.22	IC50	6000	nM	CHEMBL1689454
5.05	IC50	9000	nM	CHEMBL1689447
5.05	IC50	9000	nM	CHEMBL1689448
5.05	IC50	9000	nM	CHEMBL1689450

PubChem BioAssay actives

36 with measured affinity, of 56 total; 26 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(4S)-5-[[(2S)-1-[[(4R,7S,13S,16S,19S,22S,25S,28R)-4-[[(2R,3R)-1-[[(2S)-6-acetamido-1-[(1-amino-2-methyl-1-oxopropan-2-yl)amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-19-[(2S)-butan-2-yl]-22-[(4-hydroxyphenyl)methyl]-7,25-bis(1H-imidazol-5-ylmethyl)-10,10-dimethyl-13-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-16-[4-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]butyl]-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacos-28-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]-methylamino]-5-oxopentanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0001	uM
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2R,3R)-1-[[(2R)-1-[[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-9-[(2S)-butan-2-yl]-12-[(4-hydroxyphenyl)methyl]-15,26-bis(1H-imidazol-5-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-6-[4-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]butyl]-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0003	uM
(4S)-4-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-5-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-9-[(2S)-butan-2-yl]-12-[(4-hydroxyphenyl)methyl]-15,26-bis(1H-imidazol-5-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-6-[4-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]butyl]-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0003	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-oxo-1-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]hexan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(4-aminobutyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	0.0020	uM
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]-methylamino]-5-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2R,3R)-1-[[(2R)-1-[[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-9-[(2S)-butan-2-yl]-12-[(4-hydroxyphenyl)methyl]-15,26-bis(1H-imidazol-5-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-6-[4-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]butyl]-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	0.0030	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-6-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]hexan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0040	uM
(3S)-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-acetamido-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-6-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]hexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	0.0040	uM
(3S)-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-acetamido-1-[[(2S)-1-[[(2S)-6-amino-1-oxo-1-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-oxobutanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0050	uM
(3S)-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-acetamido-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-15-[4-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]butyl]-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-oxobutanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0060	uM
(3S)-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-acetamido-1-[[(2S)-1-[[(2S)-6-amino-1-oxo-1-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(4-acetamidobutyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-oxobutanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0080	uM
8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one	730066: Binding affinity to recombinant PIGF1 (unknown origin) measured for 60 seconds by surface plasmon resonance assay	kd	0.0082	uM
(3S)-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-acetamido-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-6-[4-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]butyl]-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-oxobutanoic acid	587577: Binding affinity to human PlGF-1	kd	0.0090	uM
(2R,3S)-8-[(2S,4R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol	730066: Binding affinity to recombinant PIGF1 (unknown origin) measured for 60 seconds by surface plasmon resonance assay	kd	0.0110	uM
(1R,5R,6S,13S,21R)-13-(3,4-dihydroxyphenyl)-5-(4-hydroxyphenyl)-4,12,14-trioxapentacyclo[11.7.1.02,11.03,8.015,20]henicosa-2(11),3(8),9,15,17,19-hexaene-6,9,17,19,21-pentol	730066: Binding affinity to recombinant PIGF1 (unknown origin) measured for 60 seconds by surface plasmon resonance assay	kd	0.0230	uM
(3S)-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(4-aminobutyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxo-3-[[(2S)-2-[[2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetyl]amino]-3-phenylpropanoyl]amino]butanoic acid	587577: Binding affinity to human PlGF-1	kd	0.2000	uM
(1R,5R,6S,13S,21R)-5,13-bis(3,4-dihydroxyphenyl)-4,12,14-trioxapentacyclo[11.7.1.02,11.03,8.015,20]henicosa-2(11),3(8),9,15,17,19-hexaene-6,9,17,19,21-pentol	730066: Binding affinity to recombinant PIGF1 (unknown origin) measured for 60 seconds by surface plasmon resonance assay	kd	0.3940	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-15-(4-aminobutyl)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1,6-dioxohexan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	1.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1,6-dioxohexan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	1.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(4-aminobutyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	1.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	1.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-15-(4-aminobutyl)-23-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-6-[(1R)-1-hydroxyethyl]-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	5.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(4R,7S,10S,13S,19S,22S,25S,28R)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-25-(2-amino-2-oxoethyl)-7-(1H-imidazol-5-ylmethyl)-22-(1H-indol-3-ylmethyl)-10-methyl-13-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-19-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacos-28-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	5.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(4-aminobutyl)-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	6.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(2S,3S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-15-(4-aminobutyl)-9-[(2S)-butan-2-yl]-6-(3-carbamimidamidopropyl)-12-[(4-hydroxyphenyl)methyl]-26-(1H-imidazol-5-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	9.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(3S,9S,12S,15S,18R,23R,26S,29S)-23-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-15-(2-amino-2-oxoethyl)-26-(1H-imidazol-5-ylmethyl)-12-(1H-indol-3-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-9-propan-2-yl-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	9.0000	uM
(3S)-3-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(2S,3S)-1-[[(3S,6S,9S,12S,15S,18R,23R,26S,29S)-15-(4-aminobutyl)-23-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-9-[(2S)-butan-2-yl]-6-(3-carbamimidamidopropyl)-12-[(4-hydroxyphenyl)methyl]-26-(1H-imidazol-5-ylmethyl)-3-(2-methylpropyl)-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontan-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid	587565: Inhibition of human PlGF-1-VEGFR-1 interaction by ELISA	ic50	9.0000	uM

CTD chemical–gene interactions

105 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium Chloride	affects expression, decreases expression, increases expression, affects reaction	6
sodium arsenite	decreases expression, increases abundance, increases expression	4
Benzo(a)pyrene	increases expression, increases methylation	4
nickel sulfate	affects cotreatment, increases expression	3
Resveratrol	affects cotreatment, decreases expression, increases expression	3
Particulate Matter	decreases expression, increases abundance, affects expression, increases expression	3
perfluorooctane sulfonic acid	decreases reaction, increases expression, decreases expression	2
entinostat	increases expression, affects cotreatment	2
Sunitinib	increases expression	2
Air Pollutants	increases abundance, decreases expression, affects expression	2
Arsenic	increases abundance, increases expression	2
Estradiol	affects cotreatment, increases expression	2
Colforsin	increases expression, decreases reaction	2
Nickel	increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	increases expression, increases methylation	2
Zinc	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	increases expression	1
GSK2656157	decreases reaction, increases expression	1
ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate	decreases expression	1
ODN2006	decreases secretion	1
PF-06840003	decreases expression, decreases reaction	1
4-methylumbelliferone 8-carbaldehyde	increases expression, decreases reaction	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
lead acetate	affects cotreatment, increases expression	1
sodium arsenate	increases expression, increases abundance	1
2-methyl-4-isothiazolin-3-one	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1692887	Binding	Binding affinity to human PlGF-2	Evolution of potent and stable placental-growth-factor-1-targeting CovX-bodies from phage display peptide discovery. — J Med Chem

Cellosaurus cell lines

9 cell lines: 6 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A5H1	SEES3-1V human PGF, clone1	Embryonic stem cell	Male
CVCL_A5H2	SEES3-1V human PGF, clone2	Embryonic stem cell	Male
CVCL_A5H3	SEES3-1V human PGF, clone3	Embryonic stem cell	Male
CVCL_B8MG	Abcam HCT 116 PGF KO	Cancer cell line	Male
CVCL_B9A7	Abcam MCF-7 PGF KO	Cancer cell line	Female
CVCL_B9PM	Abcam A-549 PGF KO	Cancer cell line	Male
CVCL_D7WV	Ubigene A-549 PGF KO	Cancer cell line	Male
CVCL_TD00	HAP1 PGF (-) 1	Cancer cell line	Male
CVCL_TD01	HAP1 PGF (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.